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Abstract
Adenosine, an important signaling molecule in asthma, produces bronchoconstriction in asthmatics.
Adenosine produces bronchoconstriction in allergic rabbits, primates, and humans by activating
A1 adenosine receptors (ARs). Effects of L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-
(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione] a water-soluble, small
molecule A1 AR antagonist were investigated on early and late phase allergic responses (EAR and
LAR) in a hyper-responsive rabbit model of asthma. Rabbits were made allergic by intraperitoneal
injections of house dust mite [HDM; 312 allergen units (AU)] extract within 24 h of their birth.
Booster HDM injections were given weekly for 1 month, biweekly for 4 months, and continued
monthly thereafter. Hyper-responsiveness was monitored by measuring lung dynamic compliance
(Cdyn), after histamine or adenosine aerosol challenge in allergic rabbits. Hyper-responsive rabbits
were subjected to aerosol of HDM (2500 AU), 1 h after intragastric administration of L-97-1 (10
mg/kg) solution or an equivalent volume of saline. Cdyn was significantly higher after treatment
with L-97-1 compared with untreated controls (p < 0.05 n = 5). Histamine PC30 was significantly
higher (p < 0.05; n = 5) after L-97-1 at 24 h compared with histamine PC30 at 24 h after HDM.
Adenosine PC30 was significantly higher at 15 min and 6 h after L-97-1 compared with control (p <
0.05; n = 5). L-97-1 showed strong affinity for human A1 ARs in radioligand binding studies and no
inhibition toward human phosphodiesterase II, III, IV, and V enzymes. These data suggest that L-97-1
produces a significant reduction of histamine or adenosine-induced hyper-responsiveness and HDM-
induced EAR and LAR in allergic rabbits by blocking A1 ARs and may be beneficial as an oral
therapy for human asthma.
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[p-(2-carboxyethyl)phenethylamino]-5′-N-ethylcarboxamidoadenosine; ANOVA, analysis of
variance; MANOVA, multiple analysis of variance; PDE, phosphodiesterase; ASM, airway smooth
muscle
Adenosine is an endogenous nucleoside-signaling molecule and acts on adenosine receptors
(ARs) to produce a number of physiological effects in humans, including bronchoconstriction
and lung inflammation. Moreover, it is becoming increasingly apparent that adenosine is an
important signaling molecule in human asthma. When administered by inhalation, adenosine
produces concentration-dependent bronchoconstriction in patients with asthma, but not in
normal subjects (Cushley et al., 1983; Polosa, 2002; Rorke and Holgate, 2002). Adenosine
levels are increased in the bronchoalveolar fluid of asthmatics and also in the plasma of patients
with exercise-induced asthma (Driver et al., 1993; Vizi et al., 2002). There is also an association
between allergen exposure and adenosine monophosphate (AMP) responsiveness in asthmatics
(Currie et al., 2003). In asthma, the airway response to AMP seems to correlate more closely
with disease activity than the response to other more conventional provocative agents, such as
methacholine (de Meer et al., 2002).
Adenosine may contribute to the pathogenesis of airway responsiveness and airway
inflammation associated with asthma by acting on specific cell surface ARs (Polosa, 2002;
Rorke and Holgate, 2002; Livingston et al., 2004). Adenosine receptors belong to the
superfamily of receptors known as G protein-coupled receptors. Four adenosine receptor
subtypes, A1, A2A, A2B, and A3, are expressed in the lung, have been cloned in humans, and
have been investigated as potential targets for drug development in asthma (Bjorck et al.,
1992; Polosa, 2002; Rorke and Holgate, 2002). By acting through A1 ARs on a number of
different human cell types, adenosine produces bronchoconstriction, inflammation, increased
endothelial cell permeability and mucin production, a cardinal feature of airway remodeling,
which increase airflow obstruction in asthma (Cronstein et al., 1990, 1992; Salmon et al.,
1993; Marquardt, 1997; Wilson and Batra, 2002; McNamara et al., 2004).
Emerging scientific and clinical data support that the A1 AR is an important AR target in human
asthma. Bamifylline is an A1 AR antagonist approved for the treatment of asthma in Europe
(Abbrachio and Cattabeni, 1987; Catena et al., 1988; Morandini, 1988). Theophylline produces
its anti-asthma effects in humans with an effective therapeutic plasma level that is less than
that required to inhibit human phosphodiesterase enzymes and that would produce antagonism
of ARs (Barnes, 2003). Further validation that the A1 AR is an important target in human
asthma is supported by positive results in human asthmatics from early clinical trials with EPI
2010, a respiratory antisense oligonucleotide to the human A1 AR (Ball et al., 2003).
Previously, it was reported that the allergic rabbit model simulates the human condition of
asthma (Metzger et al., 1989; Herd and Page, 1996). Both allergic rabbits and allergic humans
behave similarly to airway hyperreactivity to adenosine, histamine, acetylcholine, and platelet-
activating factor. After an inhalational challenge, adenosine increases airway reactivity in both
allergic humans and allergic rabbits, but not in nonallergic, normal humans, and normal rabbits
(Cushley et al., 1983; Ali et al., 1992a, 1994c). With the use of selective pharmacological
probes for ARs, the A1 AR clearly mediates adenosine-induced acute bronchoconstrictor
responses in the allergic rabbit model of asthma (Ali et al., 1994c; El-Hashim et al., 1996;
Nyce and Metzger, 1997). Moreover, in small airways from allergic rabbits, the expression of
the A1 AR is increased compared with that in small airways from normal rabbits (Ali et al.,
1994b).
L-97-1 is a water-soluble small molecule A1 AR antagonist with high affinity and high
selectivity for the human A1 AR. It is under development as an oral antiasthma treatment for
humans. In an allergic rabbit model of asthma, after oral administration, the effect of L-97-1
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on house dust mite (HDM) allergen induced early (bronchoconstrictor) and late (inflammatory)
allergic responses (EARs and LARs, respectively) as well as histamine and adenosine-induced
bronchial hyper-responsiveness were determined.
Materials and Methods
Induction of Allergic Asthma in Rabbits.
Inbred New Zealand White Pasturella-free rabbit littermates were bred and immunized
intraperitoneally within 24 h of birth with 312 allergen units (AU) of house dust mite (HDM;
Greer Laboratories, Lenoir, NC) suspended in 10% kaolin. The rabbits also received regular
rabbit diet and water ad libitum. The injections were repeated weekly for 4 weeks, biweekly
for 2 months, and then monthly until the end of the experiment. These rabbits preferentially
produce allergen-specific IgE antibody, typically respond to aeroallergen challenge with an
early and late phase asthmatic response, and show increased bronchial hyper-responsiveness
(Metzger, 1990). Sensitized rabbits show higher titers of HDM-specific IgG (0.505–1.097 U)
compared with nonsensitized rabbits (0.062–0.262 U). The rabbits were kept in community
cages with 12-h periods of light and dark cycles and were maintained on a standard laboratory
rabbit diet with access to water ad libitum. All animal care and experimentation was approved
and carried out in accordance with the East Carolina University Institutional Animal Care and
Use Committee and in accordance with the principles and guidelines of the National Institutes
of Health Guide for the Care and Use of Laboratory Animals.
Pulmonary Function Measurements.
Four months after birth, the rabbits were screened for adenosine/histamine sensitivity by
measuring lung dynamic compliance (Cdyn) changes in response to aerosol administration of
serial dilutions of adenosine or histamine (0.17–20 mg/ml). Briefly, rabbits were anesthetized
and relaxed with 1.5 ml of a mixture of ketamine hydrochloride (35 mg/kg) and acepromazine
maleate (1.5 mg/kg) administered intramuscularly. After induction of anesthesia, the rabbits
were laid supine on a soft molded animal board in a comfortable position. A salve was applied
to the eyes, and they were closed. Each animal was then intubated with a 3.0-mm flexible
cuffed Murphy 1 endotracheal tube (Webster Veterinary Supplies, Charlotte, NC) as described
previously (Zavala and Rhodes, 1973). A polyethylene catheter of ~2.4 mm o.d. (BD
Biosciences, Clay Adams, Parsippany, NJ) with an attached thin-walled latex balloon was
passed into the esophagus and maintained at the same distance (~16 cm) from the mouth
throughout the experiment. The endotracheal tube was attached to a heated Fleish Pneumotach
(size 00; DEM Medical, Richmond, VA) and flow (V) was measured using a Validyn
differential pressure transducer (model DP-45-16-1927; Validyn Engineering, Northridge,
CA) driven by a Gould carrier amplifier (model 11-4113; Gould Electronics, Cleveland, OH).
The esophageal balloon was attached to one side of Validyn differential pressure transducer,
and the other side was attached to the outflow of the endotracheal tube to obtain transpulmonary
pressure (Ptp). Flow was integrated to give a continuous tidal volume. Measurements of total
lung resistance (Rt) and dynamic compliance (Cdyn) were calculated at isovolumetric and zero
flow points. Recording of flow, volume, and pressure were made amplified on an eight-channel
Gould 2000W high-frequency amplifier. Cdyn was calculated using total volume and the
difference in Ptp at zero flow. Rt was calculated as the ratio of Ptp and V at midtidal lung
volumes. These calculations were made automatically with the Buxco automatic pulmonary
mechanics respiratory analyzer (Biosystem XA system; Buxco Electronic Inc., Sharon, CT)
running on a personal computer, as described previously (Giles et al., 1971). A period of 15
min is allowed after intubation to allow the animals to attain a steady baseline respiration before
any procedure.
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Measurement of Bronchial Hyper-Responsiveness (BHR).
At 4 months, each of the sensitized rabbits were initially administered histamine or adenosine
by aerosol to determine its baseline hyperresponsiveness. Aerosols of either normal saline,
histamine, or adenosine were generated by a DeVilbiss nebulizer (DeVilbiss, Somerset, PA)
for 2 min at each dose. The ultrasonic nebulizer produced aerosol droplets, of which 80% were
<5 μm in size. Histamine or adenosine aerosol was administered in increasing concentrations
(0.17–10 mg/ml) with measurements of pulmonary function for 15 min after 3 min of aerosol
for each dose. Animals were not exposed to higher doses of histamine or adenosine after their
PC30 [concentration (milligrams per milliliter) required to produce 30% reduction in Cdyn]
was reached. An initial saline aerosol was used to establish baseline. Pulmonary function was
summated every 10 breaths of even gradation. Data from spastic breathing were filtered out as
artifact. The drug-induced response for each treatment was taken as the lowest consistent Cdyn
value with 3 min of treatment. This point was typically achieved within the first 2 min after
treatment. Allergic rabbits that do not attain a PC30 to histamine or adenosine above 20 and 10
mg/ml, respectively, were excluded from the study. Less than 1% of all sensitized rabbits did
not attain this PC30 to histamine or adenosine.
Effect of L-97-1 on Allergen-Induced EAR and LAR.
Sensitized rabbits exposed to allergen aerosol are susceptible to an allergic response
characterized by a phasic bronchoconstriction (EAR) and airway inflammation (LAR). The
following procedure was designed to investigate the effect of L-97-1 on HDM allergen-induced
EAR and LAR in the allergic rabbit model. Rabbits that had not been used for any airway
provoking procedure were anesthetized and intubated as described above. After a steady
baseline respiration is attained, the animals were aerosolized with 2500 AU of HDM allergen
for about 10 min or until the allergen was exhausted. Pulmonary function (Cdyn) was then
measured at 15-min intervals during the next 6 h to determine the effect of HDM allergen on
early (0–60 min) and late (120–360 min) allergic responses (EAR and LAR, respectively). The
same procedure was repeated with L-97-1 (10 mg/kg) oral gavage administered 1 h before
allergen challenge in the same animals after at least a 2-week washout period. Anesthesia was
maintained with a mixture of ketamine/acepromazine (80:20) at a dose of 0.15 mg/kg given
every 45 min to 1 h.
Effect of L-97-1 on Allergen-Induced BHR to Histamine.
To determine the effect of L-97-1 on BHR, the following protocol was used. Allergic rabbits
that had not been aerosolized with allergen, histamine, or adenosine for at least 2 weeks (n =
5) were aerosolized with histamine as described above to determine their baseline PC30 to
histamine and BHR to histamine. Twenty-four hours later, the rabbits were given an aerosol
challenge of 2500 AU of HDM allergen. Then, BHR measurement with histamine aerosolized
challenge was repeated at 24 h after allergen challenge. The same protocol was employed to
test the effectiveness of L-97-1 (10 mg/kg) administered as an oral gavage 1 h before HDM
allergen challenge on BHR to histamine.
Effect of L-97-1 on BHR to Adenosine.
To determine the effect of L-97-1 on BHR to adenosine, the following protocol was used.
Allergic rabbits that had not been aerosolized with allergen, histamine, or adenosine for at least
2 weeks (n = 5) were aerosolized with adenosine as described above to determine their baseline
PC30 to adenosine. The next day, 1 h after oral administration of L-97-1 (10 mg/kg),
measurements of BHR to adenosine were again taken at 15 min, 6 h, and 24 h in the same
rabbits.
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Plasma Levels of L-97-1.
An ear artery sample of blood was collected in tubes containing EDTA at 0 min, 15 min, 30
min, 1 h, 2 h, 3 h, 6 h, 8 h, and 24 h after L-97-1 administration. The samples were centrifuged
at 5000g for 5 min, and plasma was collected and frozen at −20°C until used. Serum levels of
L-97-1 were measured by electrospray liquid chromatography/tandem mass spectrometry
method validated at Prevalere Life Sciences, Inc. (Whitesboro, NY).
Effect of L-97-1 on Contractile Responses in in Vitro Muscle Tension Studies in Small
Airways of Allergic Rabbits.
Allergic rabbits were euthanized with sodium pentobarbital (100 mg/kg i.v) in accordance with
the guidelines of the Animal Use and Care Committee of the Brody School of Medicine (East
Carolina University). Lungs were removed and immediately placed in oxygenated, ice-cold
Krebs-Henseleit buffer, pH 7.4. Secondary (5 mm) and tertiary (2–4 mm) airways were
dissected out of the lung tissue. During the dissection, tissue was immersed in ice-cold
oxygenated buffer. Bronchioles were cut into small rings and mounted in 10-ml organ baths
with stainless steel hooks and surgical thread (000) with a resting tension of 500 mg. Organ
baths contained oxygenated and heated (37°C) Krebs-Henseleit buffer. Bronchiole rings were
equilibrated with the organ bath environment for 2 h, with a complete change of buffer every
15 min. Contractions of each bronchiole ring were expressed as a percentage of the force
measured when rings were treated with 50 mM KCl. Isometric tension was measured by force
displacement transducers (BIOPAC Systems Inc., Santa Barbara, CA) connected to BIOPAC
MP100 data acquisition and analysis hardware from BIOPAC Systems Inc. After bronchioles
were stimulated with KCl and the buffer in each organ bath was exchanged three times in rapid
succession, tissues were given a 30 min recovery period before challenge with the increasing
concentrations of the nonselective AR agonist 2-chloroadenosine (2-CADO) (5 × 10−5 and
10−4 M). After washing out the agonist from the organ baths, the bronchioles were given a 30-
min period to return to baseline tension before a 30-min treatment with L-97-1 at a
concentration of 10−6 or 10−5 M. Bronchioles were again challenged with the same
concentrations of 2-CADO. This protocol was repeated on the bronchioles using a single dose
of histamine (5 × 10−6 M) before and after treatment with L-97-1. Each experimental condition
was performed in bronchioles from three different rabbits in replicates of 8.
Radioligand Binding Assays.
To determine the affinity for L-97-1 for the human A1 AR, A2A AR, and A2B ARs, the
following protein sources were used: membranes from human pulmonary artery endothelial
cells (Cambrex Bio Science Walkersville, Inc., Walkersville, MD) expressing the human A1
AR and membranes from human embryonic kidney 293 cells expressing the recombinant
human A2A and human A2B ARs (Receptor Biology, Inc., Beltsville, MD).
Human Pulmonary Artery Endothelial Cells (PAECs): Culture and Membrane Preparation.
Human PAECs were obtained from Cambrex Bio Science Walkersville, Inc., and grown in a
multilayer tissue culture vessel for membrane preparation in an atmosphere of 95% O2 and 5%
CO2. The cells were grown and maintained in medium recommended by the manufacturer,
EMB-2 (Cambrex Bio Science Walkersville, Inc.) which contains 2.0% fetal bovine serum.
The cells were washed three times with phosphate-buffered saline and then suspended in lysis
buffer (10 mM Tris HCl, pH 7.4, containing 5 mM EDTA, 10 μg/ml soybean trypsin inhibitor,
10 μg/ml benzamidine, and 2 μg/ml pepstatin). The cells were homogenized by sonication.
The homogenate was centrifuged at 1000g at 4°C for 10 min. The supernatant was centrifuged
at 30,000g for 45 min. The pellet was reconstituted in reconstitution buffer (50 mM Tris HCl,
pH 7.4, 5 mM EDTA, 10 mM MgCl2, 10 μg/ml soybean trypsin inhibitor, 10 μg/ml
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benzamidine, and 2 μg/ml pepstatin). The protein content was determined by Bradford reagent
using bovine serum albumin as standard. The aliquots were stored at −80°C until used.
Determination of the Affinity of L-97-1 for Human A1 and Recombinant Human A2A, and
A2B Adenosine Receptors in Inhibition, Competition Radioligand Binding Assays.
Radioligand competition binding experiments were performed with membranes from human
PAECs or human embryonic kidney-transfected cells in a total volume of 0.2 ml in incubation
buffer at room temperature with the selective adenosine receptor antagonist radioligands and
under the conditions as determined or recommended by the supplier of the membranes that are
presented in Table 1. After incubation, the samples were filtered rapidly under vacuum through
polyethyleneimine-treated filters and washed four times with 3 ml of ice-cold buffer using a
cell harvester (Skatron, Lier, Norway). The filters were dried and counted for radioactivity
with the use of a liquid scintillation counter (PerkinElmer Life and Analytical Sciences, Boston,
MA). Two to four experiments were performed and assayed in duplicate.
The affinity of L-97-1 for the recombinant human A3 AR was determined in another laboratory
(Dr. Gary L. Stiles, Duke University Medical Center, Durham, NC) in Chinese hamster ovary
cells expressing the recombinant human A3 AR with the use of N6-(4-amino-3-[125I]
iodobenzyl)adenosine-5′-N-methylcarboxamide, as the competing radioligand in competition
radioligand binding assays (n = 2).
To further validate the selectivity of L-97-1 for the human A1 AR, the affinity of L-97-1 for a
number of other receptors was determined by NovaScreen (Hanover, MD) with the use of
radioligand competition binding assay protocols similar to that described above and selective
radioligands for the following receptors. L-97-1 (10 μM) was tested in competition radioligand
binding assays for the rat adrenergic, α1 and α2, peripheral benzodiazepine, nonselective
dopamine, glutamate [α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate,
NMDA agonist, and glycine NMDA sites), strychnine-sensitive glycine, H1 histamine, H2
histamine, and H3 histamine, non-selective central muscarinic, nonselective peripheral
muscarinic, nonselective serotonin, and nonselective opiate receptors.
Assay for Inhibition of Human Phosphodiesterase Enzymes.
Assays for inhibition of human phosphodiesterase enzymes II, III, IV, and V, were determined
by Cerep (Celle l’Evescault, France). Test compounds, L-97-1 (100 μM) and theophylline (100
μM), were tested in duplicate. In each experiment, the respective reference compound was
tested at a minimum of seven concentrations in duplicate to obtain an inhibition curve to
validate the experiment. Radioactivity was determined with a scintillation counter (TopCount;
PerkinElmer Life and Analytical Sciences). General procedures and experimental conditions
are given in Tables 2 and 3, respectively.
Chemicals.
[3H]DPCPX and [3H] CGS 21680 were purchased from PerkinElmer Life and Analytical
Sciences. (R)-N6-Phenylisopropyladenosine, 2-chloro-N6-cyclopentyladnenosine, 5′-N-
ethylcarboxamidoadenosine, DPCPX, and all other common reagents of analytical grade were
purchased from Sigma-Aldrich (St. Louis, MO). L-97-1 was custom synthesized by ChemSyn
Laboratories (Lenexa, KS) and provided by Constance N. Wilson (Endacea, Inc., Research
Triangle Park, NC).
Statistical Analysis.
To assess the effect of L-97-1 on the changes in pulmonary function after adenosine, histamine,
and allergen challenge, the area under the curve in square centimeters is digitized by computer-
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assisted plenometry for each rabbit during a 6-h period after adenosine and allergen challenge
and at 24 h after adenosine, histamine, and allergen challenge. The early and late phase
responses are determined at 0 to 1 h and 1 to 6 h, respectively, as previously established in this
allergic rabbit model. The percentage change in Cdyn is calculated for each time point for
allergen challenge (every 15 min for 6 h). Statistical significance in time series between the
control and drug-treated groups were determined by two-way multiple ANOVA (MANOVA).
Comparisons between control and test values at the same time point were determined by post
hoc comparison of two means. Airway hyper-responsiveness for adenosine and histamine is
calculated by determining the concentration of adenosine or histamine (milligrams per
milliliter) required to reduce the Cdyn by 30% from baseline (PC30). Significance for histamine
responses is determined by comparing these values using ANOVA with post hoc least square
difference determination between values and for adenosine responses using Kruskal-Wallis
test. In the in vitro muscle tension studies statistical significance of the results was determined
using the Student’s t test for paired data. Results are expressed as mean ± S.E.M. A value of
p < 0.05 is considered significant. Radioligand binding data were analyzed by nonlinear
regression using a sigmoidal dose-response curve with variable slope (Prism version 3.0;
GraphPad Software Inc., San Diego, CA).
Results from assays for inhibition of human phosphodiesterase enzymes are expressed as a
percentage of inhibition of control values obtained in the presence of the test compounds.
IC50 values (concentration causing a half-maximal inhibition of control values) and Hill
coefficients (nH) were determined for the reference compounds by nonlinear regression
analysis of their inhibition curves. These parameters were obtained by Hill equation curve
fitting. The IC50 values obtained for the reference compounds have passed the required
inspections. They are within accepted limits of historic averages obtained ± 0.5 log units.
Results
Effect of L-97-1 on EAR and LAR.
Figure 1 shows the effect of L-97-1 (10 mg/kg oral) administration on HDM allergen-induced
EAR and LAR. L-97-1-treated rabbits showed significantly higher Cdyn, up to 6 h compared
with the untreated control group (n = 5). The curve is significant at all time points after 30 min
(MANOVA; p < 0.05).
Effect of L-97-1 on BHR to Histamine.
Figure 2 shows the effect of L-97-1 (10 mg/kg oral) administration on HDM-induced bronchial
hyper-responsiveness to histamine in the allergic rabbits. Allergen challenge significantly
reduced PC30 (histamine) to 4 ± 1 mg/ml 24 h after allergen challenge from the baseline
PC30 of 15 ± 4 mg/ml (no allergen, no drug) (p < 0.05; n = 5). Administration of L-97-1 (10
mg/kg oral), 1 h before allergen challenge markedly increased the PC30 from 4 ± 1 mg/ml (24
h after allergen challenge with no drug) to 20 ± 8 mg/ml (24 h after allergen challenge plus
L-97-1) (p < 0.05; n = 5).
Effect of L-97-1 on BHR to Adenosine.
Figure 3 shows the effect of L-97-1 (10 mg/kg oral) administration on bronchial hyper-
responsiveness to adenosine in allergic rabbits. PC30 adenosine increased significantly from
baseline 4.14 ± 0.83 to 38.33 ± 1.67 mg/ml (p < 0.05; n = 5), 15 min after the single
administration of L-97-1 (10 mg/kg administered as oral gavage 1 h before adenosine
challenge). The PC30 after 6 h (11.67 ± 4.41 mg/ml) and 24 h (5.83 ± 2.2 mg/ml) of single
administration of L-97-1 (10 mg/kg oral) was higher compared with baseline reaching
statistical significance at 6 h compared with the baseline (p < 0.05; n = 5).
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Plasma Levels of L-97-1.
Table 4 shows the levels of L-97-1 in a 24-h period after a single oral administration of L-97-1
(10 mg/kg). The effect of L-97-1 on LAR and adenosine-induced bronchial hyper-
responsiveness at 6 h after administration of L-97-1 (10 mg/kg) correlates with a plasma level
of 13 ng/ml. L-97-1 blocked bronchial hyper-responsiveness significantly increasing the
PC30 histamine at 24 h after allergen challenge. This lasting effect of L-97-1 at 24 h suggests
that a plasma level of 3 ng/ml is an effective plasma concentration.
Effect of L-97-1 on Contractile Responses in in Vitro Muscle Tension Studies in Small
Airways of Allergic Rabbits.
Figure 4 shows that in in vitro muscle tension pharmacology studies in small airways from
allergic rabbits, L-97-1 (10−5 and 10−6 M) selectively blocks the contractile responses of 2-
CADO (5 × 10−5 and 10−4 M) (p ≤ 0.006) in a concentration-dependent manner without
blocking those of histamine (5 × 10−6 M).
Radioligand Binding Studies.
Affinities of L-97-1 and other reference adenosine receptor ligands to human A1, A2A, and
A2B ARs are presented in Table 5. L-97-1 has high affinity (580 nM) and high selectivity for
the human A1 AR with no binding to recombinant human A2A or A2B ARs at high concentration
(≤100 μM). Moreover no binding was demonstrated for L-97-1 (≤ 1 mM) to the recombinant
human A3 AR (data not shown). There was no binding of L-97-1 to rat adrenergic, α1 and α2,
peripheral benzodiazepine, non-selective dopamine, glutamate (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid, kainate, NMDA agonist, and glycine NMDA sites),
strychnine-sensitive glycine, H1 histamine, H2 histamine, and H3 histamine, nonselective
central muscarinic, nonselective peripheral muscarinic, nonselective serotonin, and
nonselective opiate receptors (data not shown).
Phosphodiesterase Inhibition Assays.
The effects of L-97-1 (100 μM) and theophylline (100 μM) on the human phosphodiesterase
II, III, IV, and V, enzymes are summarized in Table 6 where the IC50 values for the reference
compounds are also indicated. As opposed to theophylline (100 μM), which inhibits human
PDE enzymes II, III, and IV at 19, 28, and 21% inhibition, respectively, L-97-1 (100 μM) does
not inhibit human PDE enzymes II, III, IV, or V.
Discussion
In the present study, a rabbit model of allergic asthma was used to study the effects of a novel
A1AR antagonist, L-97-1, on HDM-induced early and late phase allergic responses and BHR
to histamine and adenosine. In this proof of concept study, administration of a high dose for
L-97-1 (10 mg/kg) given orally to allergic rabbits significantly improved both EAR and LAR
responses and increased lung compliance (Cdyn) after HDM allergen challenge. Pretreatment
with this same dose of L-97-1 also blocked BHR to both adenosine and histamine in allergic
rabbits. Pharmacokinetic profile of L-97-1 in plasma shows that L-97-1 produced these anti-
asthma effects in allergic rabbits at plasma levels (3–13 ng/ml; 10 nM) that do not inhibit human
phosphodiesterase II, III, IV, or V enzymes. Radioligand binding studies in human ARs and
other receptors confirm that this compound has high affinity and high selectivity for the human
A1 AR. Moreover, in vitro pharmacology studies in small airways of allergic rabbits suggest
that L-97-1 selectively produces its antiasthma effects in allergic rabbits by blocking ARs.
The endogenous nucleoside, adenosine is reported to produce acute bronchoconstriction
through indirect effects by inducing the release of preformed and newly formed mediators from
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mast cells and possibly direct effects on airway smooth muscle (ASM) and adrenergic nerve
endings (Polosa, 2002; Livingston et al., 2004). Previously, it is reported that A1 ARs on ASM
are a direct target for adenosine in humans and allergic rabbits (Ali et al., 1994b; Nyce and
Metzger, 1997; Mundell et al., 2001). Moreover, in the allergic rabbit model of asthma,
administration of a respiratory antisense oligodeoxynucleotide specific for the A1 AR, EPI
2010, reduced the density of A1 ARs on ASM and attenuated adenosine-induced acute
bronchoconstriction (Nyce and Metzger, 1997). In the present study, PC30 for adenosine is
increased significantly at 15 min and 6 h after oral administration of L-97-1. In previous studies,
it was reported that BHR to adenosine in allergic rabbit model of asthma is mainly due to up-
regulation of A1 ARs on ASM (Ali et al., 1994b; Nyce and Metzger, 1997). Thus, in the present
study, L-97-1 may block the BHR to adenosine in allergic rabbits due to the antagonistic action
by this A1 AR antagonist on A1 ARs on ASM.
Airway hyper-responsiveness to allergen is considered to be a hallmark of allergic asthma. The
rabbit model of allergic asthma has been previously used to test antiasthma drugs that are in
current use for treatment of human asthma (Ali et al., 1992a,c, 1994a). Both theophylline and
beclomethasone administered as inhalational treatments inhibit EAR and LAR responses in
this rabbit model of allergic asthma (Ali et al., 1992c, 1994a). Both allergic rabbits and allergic
humans share many common features of asthma. These features include airway hyperreactivity
to adenosine, histamine, acetylcholine, platelet-activating factor, development of inflammation
and permeability changes in the airways, release of mediators, including neutrophil and
eosinophil chemotactic factors, production of antigen-specific IgE antibodies, and mast cell
dependence (Larsen et al., 1984; Metzger et al., 1989; Herd and Page, 1996; Gozzard et al.,
1997; Gascoigne et al., 2003). Moreover, adenosine levels are increased in the bronchoalveolar
fluid of both humans and rabbits with allergic asthma (Ali et al., 1992b; Driver et al., 1993).
We therefore investigated the effect of L-97-1, an A1 AR antagonist in development as an oral
treatment for asthma in humans, on HDM allergen-induced EAR and LAR as well as histamine-
induced increases in BHR 24 h after allergen challenge, in the allergic rabbit model of asthma.
L-97-1 (10 mg/kg) administered 1 h before HDM allergen administration significantly
increased Cdyn at all time points after 30 min up to 6 h, thus preventing the decline in Cdyn
and blocking both EAR and LAR responses after allergen challenge in rabbits with allergic
asthma. The increase in Cdyn during the EAR response can be explained by the direct blocking
of A1 ARs on airway smooth muscle as some of the previous studies have suggested (Ali et
al., 1994b; Nyce and Metzger, 1997). Previously, it was reported that EPI 2010 reduces EAR
response in allergic rabbits and decreases the expression of A1 ARs in ASM in allergic rabbits
(Nyce and Metzger, 1997). Moreover, theophylline inhibits EAR and LAR responses in the
allergic rabbit model at a dose that is lower than that which would produce plasma levels to
inhibit PDE enzymes (Ali et al., 1992c). The inhibitory activity of L-97-1 on A1 ARs cannot
be explained by the inhibition of PDE class of enzymes, since the plasma levels of L-97-1
detected after oral administration of this compound are too low to cause any inhibition of PDE
enzymes. Together, the results of these studies suggest that L-97-1 may block allergen-induced
EAR responses by blocking activation of A1 ARs by adenosine present in bronchoalveolar
lavage fluid of allergen-challenged rabbits. This effect of L-97-1 on EAR response in allergic
rabbits may also be, in part, a function of its antagonistic effect on the release of preformed or
newly formed mediators from mast cells or adrenergic nerve terminals. A1 ARs may be up-
regulated in human mast cells which are immunologically sensitized by IgE (Peachell et al.,
1988). The effect of L-97-1 on the release of preformed or newly formed mediators, i.e.,
histamine and leukotrienes, from immunologically sensitized mast cells, are studies for future
investigations.
The bronchoconstrictor effect of adenosine in the asthmatic lung is mediated through its
specific cell surface receptors: 1) the effects of adenosine are not reproduced by inosine, the
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deaminated metabolite of adenosine, or a closely related purine nucleoside, guanosine;
however, adenosine mono- and diphosphates, i.e., AMP and ADP (which are rapidly converted
to adenosine in the lung under physiological conditions), are equipotent with adenosine as
bronchoconstrictor agents (Mann et al., 1983); 2) theophylline and bamifylline preferentially
produce their antiasthma effects in humans at concentrations that do not inhibit
phosphodiesterase enzymes (Foutillan et al., 1983; Ginesu et al., 1987; Catena et al., 1988;
Clarke et al., 1989; Spoto et al., 1995); and 3) dipyridamole, an uptake blocker of adenosine
into the cells, enhances adenosine-induced bronchoconstriction in asthmatic patients (Cushley
et al., 1986).
In humans bamifylline produces its antiasthma effects by selectively blocking A1 ARs.
Bamifylline binds to the human A1 AR and human A2A AR with higher affinity for the human
A1 AR (1.93 μM) than the human A2a AR (12.9 μM) and does not bind to human A2B or human
A3 ARs (≤100 μM; Constance N. Wilson, personal communication). The therapeutic plasma
concentration of bamifylline is 500 times less than that needed to inhibit human II, III, IV, and
V PDE enzymes (Ginesu et al., 1987; Mann et al., 1983; Constance N. Wilson, personal
communication). Moreover, in humans theophylline produces its antiasthma effects most likely
by blocking ARs. Theophylline binds nonselectively to all the human AR subtypes (Klotz et
al., 1998). The effective therapeutic plasma concentrations for theophylline in humans is 10 to
100 times below that needed to inhibit human PDE enzymes in vitro (Clarke et al., 1989).
Compared with bamifylline and theophylline, L-97-1 binds selectively to the human A1 AR.
Moreover, L-97-1 produces its antiasthma effects in allergic rabbits at concentrations that are
1000 to 10,000 times less than that needed to inhibit human PDE enzymes.
Together, these data suggest that L-97-1 is a potent, selective antagonist of A1 ARs and its
efficacy in inhibiting the allergen-induced EAR, LAR responses and attenuating BHR to
histamine after allergen challenge and adenosine-induced BHR in allergic asthmatic rabbits is
most likely related to its antagonism of A1 ARs on ASM and perhaps on mast cells, as well as
other cell types, such as inflammatory cell types that play an important role in the LAR
response. Activation of A1 ARs on human neutrophils and macrophages has been shown to
produce proinflammatory effects (Cronstein et al., 1990, 1992; Salmon et al., 1993). The effect
of L-97-1 on airway inflammation in the allergic rabbit model of asthma is an area for future
investigation.
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Fig. 1.
Lung Cdyn in HDM-challenged rabbits with (+) and without (−) L-97-1 (10 mg/kg) treatment.
HDM was administered to sensitized rabbits by aerosolization (2500 AU). L-97-1 was
administered by intragastric tube 1 h before HDM administration. Ventilation was monitored
in the anesthetized rabbits up to 6 h after HDM administration. The curve is significant at all
time points greater than 30 min, after treatment with L-97-1 (p < 0.05; MANOVA). Data are
expressed as mean ± S.E.M. (n = 5).
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Fig. 2.
Histamine responses [histamine PC30 (milligrams per milliliter)] in rabbits aerosolized with
HDM allergen with or without L-97-1 (10 mg/kg) administered by intragastric tube 1 h before
HDM administration. Control measurement PC30 histamine was taken without HDM and
without prior drug treatment. PC30 histamine was measured again 24 h after HDM or HDM +
L-97-1 treatment. Data are expressed as mean ± S.E.M. (n = 5). *, p < 0.05 compared with
control; **, p < 0.05 compared with 24 h after HDM treatment (ANOVA).
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Fig. 3.
Adenosine responses (adenosine PC30 milligrams per milliliter) in allergic rabbits with or
without L-97-1. Adenosine PC30 measurements were taken 15 min, 6 h, and 24 h after
administration of L-97-1 (10 mg/kg) by intragastric tube. Control measurements to adenosine
in allergic rabbits were taken without HDM allergen challenge and 24 h before L-97-1
administration. Data are expressed as mean ± S.E.M. (n = 5). *, p < 0.05 compared with controls
(Kruskal-Wallis test).
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Fig. 4.
Contractile responses to 2-chloroadenosine and histamine in in vitro muscle tension studies of
small airways from allergic rabbits. The percentage of contraction by 2-CADO (5 × 10−5 and
10−4 M) and histamine (5 × 10−6 M) was calculated by comparing the response of each
bronchiole to the tension produced when activated with 50 mM KCl. Each experimental
condition was performed in bronchioles from three different rabbits in replicates of eight. Data
are expressed as mean ± S.E.M. *, p < 0.006 compared with agonist without L-97-1 (Student’s
t test for paired data).
Obiefuna et al. Page 16
J Pharmacol Exp Ther. Author manuscript; available in PMC 2006 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Obiefuna et al. Page 17
TABLE 1
Assay table for determination of the affinity of L-97-1 for human A1 and recombinant human A2A and
A2B adenosine receptors in inhibition, competition radioligand binding assays
Concentration of [3H]DPCPX used in A1 AR radioligand competition binding assay was determined from
saturation radioligand binding assays in membranes from human PAECs to determine the Kd (48 nM; average
of two experiments performed in duplicate). Adenosine deaminase, [3H]DPCPX, [3H]CGS 21680 (a selective
radioligand for the A2A AR), N6-R-phenylisopropyladenosine, and 5′-(N-ethylcarboxamido)-adenosine were
used to determine nonspecific binding for the A1 AR and A2A and A2B ARs, respectively.
Human A1 AR Recombinant Human A2A AR Recombinant Human A2B AR
Protein source/total amount Human PAECs expressing
huA1 AR/10 μg
HEK-293 cells expressing
rehuA2A AR/7.4 μg
HEK-293 cells expressing rehuA2B
AR/21.2 μg
Washing buffer 50 mM Tris; pH 7.4 50 mM Tris; pH 7.4 50 mM Tris; pH 7.4
Incubation buffer 50 mM Tris; pH 7.4; 0.2 U/
ml AD
50 mM Tris; pH 7.4; 2.0 U/ml AD;
10 mM MgCl2; 1 mM EDTA
50 mM Tris; pH 7.4; 2.0 U/ml AD;
10 mM MgCl2; 1 mM EDTA; 0.1 M
benzamidine
Radioligand/concentration [3H]DPCPX/48 nM [3H]CGS 21680/21 nM [3H]DPCPX/34 nM
Nonspecific binding/
concentration
R-PIA/100 μM NECA/50 μM NECA/100 μM
Incubation time 2 h 90 min 60 min
Filter type GF/C 934/AH GF/C
hu, human; rehu, recombinant human; AD, adenosine deaminase; R-PIA, N6-R-phenylisopropyladenosine; NECA, 5′-(N-ethylcarboxamido)-adenosine.
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TABLE 2
Assay table for inhibition of human phosphodiesterase enzymes
The assays were performed using the following general procedures.
Assay Origin Reference Compound
Phosphodiesterase II (h) Differentiated U-937 cells EHNA
Phosphodiesterase III (h) Human platelets Milrinone
Phosphodiesterase IV (h) U-937 cells Rolipram
Phosphodiesterase V (h) Human platelets Dipyridamole
h, human; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine.
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TABLE 3
Assay table for inhibition of human phosphodiesterase enzymes
The experimental conditions are summarized below.
Assay Substrate Incubation Reaction Product Method of Detection
Phosphodiesterase II (h) [3H]cAMP (1 μM) 30 min/30°C [3H]5′AMP Liquid scintillation
Phosphodiesterase III (h) [3H]cAMP (0.1 μM) 30 min/30°C [3H]5′AMP Liquid scintillation
Phosphodiesterase IV (h) [3H]cAMP (1 μM) 30 min/30°C [3H]5′AMP Liquid scintillation
Phosphodiesterase V (h) [3H]cGMP (1 μM) 30 min/30°C [3H]5′GMP Liquid scintillation
h, human.
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TABLE 4
Plasma levels (nanograms per milliliter) of L-97-1 in a 24-h period after oral administration of L-97-1 (10
mg/kg)
Data are presented as mean ± S.E.M., n = 5.
Sample 15 min 30 min 1 h 2 h 3 h 6 h 8 h 24 h
Mean 140.70 116.18 73.71 23.65 20.68 12.76 13.25 3.17
S.E.M. 73.04 58.42 37.60 9.40 6.45 4.79 3.81 0.43
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TABLE 5
Affinities of L-97-1 for human A1, recombinant human A2A, and A2B adenosine receptors
The following compounds are used as competing radioligands for the A1 and A2A and A2B ARs: [3H]DPCPX
(A1 and A2B ARs) and [3H]CGS 21680 (A2A ARs). The following compounds are used as reference compounds:
DPCPX and 2-chloro-N6-cyclopentyladnenosine (CCPA) are reference compounds for the A1 AR; DPCPX is
also a reference compound for the A2B AR; CGS 21680 is a reference compound for the A2A AR. The studies
presented in this table are inhibition competition radioligand binding assays to determine the IC50 or Ki
(measurements of affinity) of the ligand for the AR. The Ki or IC50 are inversely related to the affinity of the
ligand for the receptor; i.e. the lower the Ki or IC50, the higher the affinity.
Human A1 ([
3H]DPCPX) Human A2A ([
3H]CGS 21680) Human A2B ([
3H]DPCPX)
Ligand IC50 Ki n IC50 Ki n IC50 Ki n
μM μM μM
L-97-1 1.42 ± 0.57 0.58 ± 0.33 4 >100 N.D. 3 >100 N.D. 3
DPCPX 0.08 ± 0.04 0.04 ± 0.02 4 N.D. N.D. 0.22
±0.07
0.12
±0.04
3
CCPA 0.03 ± 0.02 0.02 ± 0.01 2 N.D. N.D. N.D. N.D. 3
CGS 21680 N.D. N.D. 0.32 ± 0.22 0.16 ± 0.11 3 N.D. N.D.
N.D., not determined.
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TABLE 6
Effects of L-97-1 and theophylline on human PDE enzymes and IC50 values for the reference compounds
For the test compounds, the results are expressed as a percentage of inhibition of control activity (mean values;
n = 2).
Reference Compound
Assay L-97-1 Theophylline IC50 nH
100 μM μM
PDE II (h) — 19 EHNA 4.7 0.7
PDE III (h) — 28 Milrinone 0.39 0.8
PDE IV (h) — 21 Rolipram 0.21 0.6
PDE V (h) — — Dipyridamole 0.80 1.2
h, human; —, inhibition of less than 10%; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine.
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